Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

LLM 2021 | LLM lymphoma highlights: ATLL

Adrienne Phillips • 26 Oct 2021
LLM 2021
Lymphoma T-Cell Lymphoma Azacitidine CHOP

Adrienne Phillips, MD, Weill Cornell Medicine, New York, NY, comments on data on adult T-cell leukemia/lymphoma (ATLL) from the LLM meeting. Although studies evaluating induction regimens did not show improvements for patients with ATLL, novel promising targets are currently being explored. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.

More from Adrienne Phillips

1:20
Limitations of CAR T-cell therapy for DLBCL
Adrienne Phillips • 26 Oct 2021
1:51
Current treatments and new developments for adult ATLL
Adrienne Phillips • 26 Oct 2021
0:51
Preventing progression to ATLL in HTLV-1 carriers
Adrienne Phillips • 26 Oct 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals